FOXM1 and in situ carcinoma: When treated with cisplatin alone, FOXM1 was significantly upregulated in cisplatin-resistant cell lines, while the combination of cisplatin and paclitaxel had markedly lower FOXM1 expression (2.9- vs 1.1-fold change for YD-8/CIS, 2.8- vs 1.1-fold change for YD-9/CIS, and 4.7- vs 1.0-fold change for YD-38/CIS cell lines).